Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind active-controlled study of JNJ-78934804 in moderately to severely active Crohn's disease
CTR20262590Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of guselkumab + golimumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
guselkumab + golimumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20262590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262590.